Dr. Berd is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1652 Noble Circle
Jenkintown, PA 19046Phone+1 267-243-4987
Education & Training
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1972 - 1975
University of Pennsylvania Health SystemResidency, Internal Medicine, 1968 - 1970
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1968
Certifications & Licensure
PA State Medical License 1969 - 2024
GA State Medical License 1970 - 1977- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer Start of enrollment: 1999 Jul 01
- Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma Start of enrollment: 2005 Jun 01
Publications & Presentations
PubMed
- 28 citationsIntracellular acidification abrogates the heat shock response and compromises survival of human melanoma cells.Ronald A. Coss, C. W. Storck, Constantine Daskalakis, David Berd, Miriam L. Wahl
Molecular Cancer Therapeutics. 2003-04-01 - 85 citationsChemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study.Kashyap Patel, Kevin L. Sullivan, David Berd, Michael J. Mastrangelo, Carol L. Shields
Melanoma Research. 2005-08-01 - 46 citationsHigh-Dose Immunoembolization: Survival Benefit in Patients with Hepatic Metastases from Uveal MelanomaAkira Yamamoto, Inna Chervoneva, Kevin L. Sullivan, David J. Eschelman, Carin F. Gonsalves
Radiology. 2009-07-01
Press Mentions
Clinical Study Collaborator HCL Sends First Surgically Excised Ovarian Cancer Tumors to BioVaxys for BVX-0918 Vaccine Process DevelopmentJune 15th, 2022- Research on a ‘Universal’ Sarbecovirus Vaccine Well UnderwayApril 26th, 2022
- BioVaxys Expands Cancer Vaccine PlatformMarch 30th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
